Exelixis Net Income From Continuing Ops from 2010 to 2026

EXEL Stock  USD 42.37  0.28  0.66%   
Exelixis Net Income From Continuing Ops yearly trend continues to be quite stable with very little volatility. Net Income From Continuing Ops may rise above about 629.4 M this year. From the period between 2010 and 2026, Exelixis, Net Income From Continuing Ops regression line of its data series had sample variance of 92578.2 T and sample variance of 92578.2 T. View All Fundamentals
 
Net Income From Continuing Ops  
First Reported
1999-12-31
Previous Quarter
184.8 M
Current Value
193.6 M
Quarterly Volatility
73.6 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Exelixis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Exelixis' main balance sheet or income statement drivers, such as Interest Expense of 64.9 M, Total Revenue of 2.6 B or Gross Profit of 2.5 B, as well as many indicators such as Price To Sales Ratio of 3.96, Dividend Yield of 0.0 or PTB Ratio of 3.89. Exelixis financial statements analysis is a perfect complement when working with Exelixis Valuation or Volatility modules.
  
Build AI portfolio with Exelixis Stock
Check out the analysis of Exelixis Correlation against competitors.
For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.
Historical Net Income From Continuing Ops data for Exelixis serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Exelixis represents a compelling investment opportunity.

Latest Exelixis' Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Exelixis over the last few years. It is Exelixis' Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Exelixis' overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Exelixis Net Income From Continuing Ops Regression Statistics

Arithmetic Mean163,714,762
Coefficient Of Variation185.85
Mean Deviation238,656,191
Median111,781,000
Standard Deviation304,266,642
Sample Variance92578.2T
Range958.6M
R-Value0.70
Mean Square Error49674.9T
R-Squared0.50
Significance0
Slope42,476,256
Total Sum of Squares1481251T

Exelixis Net Income From Continuing Ops History

2026629.4 M
2025599.5 M
2024521.3 M
202392.1 M
2022182.3 M
2021231.1 M
2020111.8 M

About Exelixis Financial Statements

Exelixis investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Exelixis Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Income From Continuing Ops599.5 M629.4 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Exelixis is a strong investment it is important to analyze Exelixis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Exelixis' future performance. For an informed investment choice regarding Exelixis Stock, refer to the following important reports:
Check out the analysis of Exelixis Correlation against competitors.
For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. Projected growth potential of Exelixis fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Exelixis assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
0.725
Earnings Share
2.36
Revenue Per Share
8.288
Quarterly Revenue Growth
0.108
Return On Assets
0.1773
Investors evaluate Exelixis using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Exelixis' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Exelixis' market price to deviate significantly from intrinsic value.
It's important to distinguish between Exelixis' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Exelixis should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Exelixis' market price signifies the transaction level at which participants voluntarily complete trades.